Helix Biopharma (OTCMKTS:HBPCF) Issues Quarterly Earnings Results

Helix Biopharma (OTCMKTS:HBPCF) issued its quarterly earnings data on Friday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.

Helix Biopharma Price Performance

Helix Biopharma stock remained flat at $1.73 during trading hours on Friday. The stock has a fifty day moving average price of $1.44 and a 200-day moving average price of $0.89. The stock has a market cap of $132.43 million, a price-to-earnings ratio of -24.77 and a beta of 0.17. Helix Biopharma has a 1 year low of $0.59 and a 1 year high of $1.73.

Helix Biopharma Company Profile

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.